Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …

Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …

Although recent clinical trials targeting amyloid-β in Alzheimer's disease have shown
promising results, there is increasing evidence suggesting that understanding alternative …

Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease
mechanisms and alterations of biomarkers during the development of AD. Using cross …

The links between β-amyloid (Aβ) and tau in Alzheimer's disease are unclear. Cognitively
unimpaired persons with signs of Aβ pathology had increased cerebrospinal fluid (CSF) …

Regulation of glial activation and neuroinflammation are critical factors in the pathogenesis
of Alzheimer's disease (AD). YKL-40, a primarily astrocytic protein encoded by the gene …

Objective To perform a systematic review and meta-analysis to determine whether fluid and
imaging astrocyte biomarkers are altered in Alzheimer disease (AD). Methods PubMed and …

Introduction This study examines the utility of a multipanel of cerebrospinal fluid (CSF)
biomarkers complementing Alzheimer's disease (AD) biomarkers in a clinical research …

The plasma proteomic changes that precede the onset of dementia could yield insights into
disease biology and highlight new biomarkers and avenues for intervention. We quantified …

Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein that is
overexpressed in many pathological states. Although, like many other immune molecules …